JP2025514763A5 - - Google Patents
Info
- Publication number
- JP2025514763A5 JP2025514763A5 JP2024561852A JP2024561852A JP2025514763A5 JP 2025514763 A5 JP2025514763 A5 JP 2025514763A5 JP 2024561852 A JP2024561852 A JP 2024561852A JP 2024561852 A JP2024561852 A JP 2024561852A JP 2025514763 A5 JP2025514763 A5 JP 2025514763A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- multispecific antibody
- amino acid
- antibody according
- constant domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333293P | 2022-04-21 | 2022-04-21 | |
| US63/333,293 | 2022-04-21 | ||
| PCT/US2023/066036 WO2023205753A1 (en) | 2022-04-21 | 2023-04-20 | Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514763A JP2025514763A (ja) | 2025-05-09 |
| JP2025514763A5 true JP2025514763A5 (https=) | 2026-04-28 |
Family
ID=86425985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561852A Pending JP2025514763A (ja) | 2022-04-21 | 2023-04-20 | Ｆｃガンマ受容体への結合が低減されたキメラ重鎖定常ドメイン及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250109207A1 (https=) |
| EP (1) | EP4511398A1 (https=) |
| JP (1) | JP2025514763A (https=) |
| KR (1) | KR20250007564A (https=) |
| CN (2) | CN117597365A (https=) |
| AU (1) | AU2023255761A1 (https=) |
| CA (1) | CA3249454A1 (https=) |
| WO (1) | WO2023205753A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240252601A1 (en) | 2022-12-23 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| DE69309472T2 (de) | 1992-01-23 | 1997-10-23 | Merck Patent Gmbh, 64293 Darmstadt | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| GB9824437D0 (en) | 1998-11-06 | 1999-01-06 | Ylo Herttuala Seppo | Gene therapy |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| WO2005049094A1 (en) | 2003-11-13 | 2005-06-02 | Advantagene, Inc. | A mixed complementary viral vector for gene therapy |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| MY192182A (en) * | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| ES2623912T3 (es) * | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| CN105026430B (zh) | 2012-11-28 | 2025-03-25 | 酵活英属哥伦比亚有限公司 | 工程化免疫球蛋白重链-轻链对及其用途 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ES2821753T3 (es) | 2013-03-15 | 2021-04-27 | Lilly Co Eli | Procedimientos de producción de Fab y de anticuerpos biespecíficos |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| MX2022005330A (es) | 2019-11-05 | 2022-05-26 | Regeneron Pharma | Moleculas de union multiespecificas con scfv en el extremo nterminal. |
| US12486321B2 (en) * | 2020-01-21 | 2025-12-02 | Tavotek Biotechnology (Jiangsu) Co., Ltd | Agents that interfere with IL-1BETA receptor signalling |
-
2022
- 2022-05-03 CN CN202280047414.2A patent/CN117597365A/zh active Pending
-
2023
- 2023-04-20 KR KR1020247038245A patent/KR20250007564A/ko active Pending
- 2023-04-20 CN CN202380048565.4A patent/CN119546637A/zh active Pending
- 2023-04-20 US US18/857,898 patent/US20250109207A1/en active Pending
- 2023-04-20 AU AU2023255761A patent/AU2023255761A1/en active Pending
- 2023-04-20 WO PCT/US2023/066036 patent/WO2023205753A1/en not_active Ceased
- 2023-04-20 EP EP23725348.9A patent/EP4511398A1/en active Pending
- 2023-04-20 JP JP2024561852A patent/JP2025514763A/ja active Pending
- 2023-04-20 CA CA3249454A patent/CA3249454A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP7788113B2 (ja) | Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途 | |
| Brinkmann et al. | The making of bispecific antibodies | |
| US12522654B2 (en) | Engineered heterodimeric proteins | |
| JP2022504550A5 (https=) | ||
| Klein et al. | Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies | |
| CA3065868C (en) | Novel hetero-dimeric multi-specific antibody format | |
| KR101851380B1 (ko) | 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍 | |
| JP2015522525A5 (https=) | ||
| JP2018537966A5 (https=) | ||
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| Spasevska | An outlook on bispecific antibodies: Methods of production and therapeutic benefits | |
| JP2024507693A5 (https=) | ||
| JP2022518282A5 (https=) | ||
| JP2025514763A5 (https=) | ||
| JPWO2022102768A5 (https=) | ||
| JP2026064000A (ja) | 抗原結合分子 | |
| RU2025130619A (ru) | Биспецифические агонистические антитела к рецептору i типа, подобному рецептору активина а (alk1) | |
| Fayadat-Dilman | Novel Technologies for Generation of Bispecific Constructs | |
| RU2024126644A (ru) | Двухвалентное биспецифическое антитело и способ его получения | |
| NZ793791B2 (en) | Multispecific heavy chain antibodies with modified heavy chain constant regions | |
| RU2021132277A (ru) | Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv | |
| AR122458A1 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| EA041608B1 (ru) | Гетеродимерный полиспецифичный формат антител |